However, the absence of heterogeneity in the pooled analysis of the majority of outcomes suggests that our meta-analysis conveys the best available evidence for the use of PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel as a treatment for primary advanced or recurrent endometrial cancer. The gene discussed is CD274; the disease is endometrial cancer.